Related Experiment Video
Updated: May 13, 2026
07:22
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
Postprandial glycaemic excursions and cardiovascular risk
Rajendra Pradeepa1, Viswanathan Mohan
1Madras Diabetes Research Foundation and Dr. Mohan's Diabetes Specialities Centre, Chennai 600086.
Journal of the Indian Medical Association
|March 9, 2013
Summary
Postprandial hyperglycaemia (PPHG), or high blood sugar after meals, is increasingly linked to diabetes complications. Managing PPHG is crucial for reducing cardiovascular disease risk and improving overall health outcomes.
Area of Science:
- Endocrinology
- Cardiovascular Medicine
- Metabolic Disorders
Background:
- Postprandial hyperglycaemia (PPHG) is recognized for its contribution to micro- and macrovascular complications in diabetes.
- PPHG negatively impacts vascular endothelium function, primarily through oxidative stress.
Purpose of the Study:
- To review the association between postprandial glucose excursions and cardiovascular disease (CVD) risk.
- To highlight PPHG as a significant therapeutic target for mitigating CVD risk in diabetic patients.
Main Methods:
- Literature review of epidemiological and longitudinal studies.
- Analysis of the mechanisms linking PPHG to vascular damage.
- Examination of PPHG's contribution to glycemic control metrics like HbA1c.
Main Results:
- Elevated PPHG is an independent risk factor for cardiovascular disease and mortality.
- PPHG significantly contributes to glycosylated haemoglobin levels, especially in type 2 diabetes.
- Oxidative stress is a key mediator of PPHG's harmful effects on the vascular endothelium.
Conclusions:
- PPHG is a critical factor in the development of diabetic vascular complications.
- Targeting PPHG is essential for reducing cardiovascular risk in diabetic individuals.
- Further research and clinical strategies should focus on managing postprandial glucose levels.
Related Concept Videos
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:02Glucose Homeostasis: Regulation of Blood Glucose
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:16Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...